← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksTELORevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

TELO logoTelomir Pharmaceuticals, Inc. Common Stock (TELO) Revenue History

Annual and quarterly revenue from 2021 to 2025

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q4 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$0 (0)
Highest Quarter$0 ()

Loading revenue history...

TELO Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$0 (0)

Download Historical Data

5 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

TELO Revenue Analysis (2021–2025)

As of May 8, 2026, Telomir Pharmaceuticals, Inc. Common Stock (TELO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.

Looking at the longer-term picture, TELO's historical revenue data shows various trends over time.

When compared to Healthcare sector peers including ADTX (-97.2% YoY), AEYE (+14.5% YoY), and INVA (+13.6% YoY). Compare TELO vs ADTX →

TELO Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
TELO logoTELOCurrent$0---
ADTX logoADTX$133,985-97.2%--20796.4%
AEYE logoAEYE$40M+14.5%+14.5%-7.9%
INVA logoINVA$425M+13.6%+4.8%38.5%
LCTX logoLCTX$15M+53.2%+79.9%-251.6%
Best in groupLowest in group

TELO Historical Revenue Data (2021–2025)

Showing 5 of 5 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$0-$-10,538,849-
2024$0-$0-$-12,242,174-
2023$0-$0-$-3,942,048-
2022$0-$0-$-854,147-
2021$0-$0-$-138,131-

See TELO's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is TELO Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare TELO vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

TELO — Frequently Asked Questions

Quick answers to the most common questions about buying TELO stock.

Is TELO's revenue growth accelerating or slowing?

TELO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is TELO's long-term revenue growth rate?

Telomir Pharmaceuticals, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is TELO's revenue distributed by segment?

TELO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2025 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

TELO Revenue Over Time (2021–2025)